Clinical trial
Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens Through Improved Epidemiologic Methods
NCT05871489 is registered in ClinicalTrials.gov with Harvard Medical School (HMS and HSDM) as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens Through Improved Epidemiologic Methods
- Lead sponsor
- Harvard Medical School (HMS and HSDM)
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- September 22, 2020
- Completion date
- December 31, 2025
- Enrollment
- 800 (estimated)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.